Abeona Therapeutics (ABEO)

$5.27 +0.10 (1.93%)
Market Cap 275.83M
Revenue (ttm) 0.00
Net Income (ttm) -63.73M
EPS (ttm) N/A
PE Ratio 4.50
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.12
Volume 963,200
Avg Vol 1,286,038
Day's Range N/A - N/A
Shares Out 54.19M
Stochastic %K 62%
Beta 1.12
Analysts Strong Sell
Price Target $20.64

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 813 4701
Address:
6555 Carnegie Avenue, 4th Floor, Cleveland, United States
William_55555
William_55555 Feb. 3 at 9:15 PM
$ABEO what does Greg Gin at company IR do alp day? Clearly scroll on instagram. Guy has got such a cake job
1 · Reply
Pharma3000
Pharma3000 Feb. 3 at 8:49 PM
$ABEO Just waitđź‘Ś
0 · Reply
StricklandTrades
StricklandTrades Feb. 3 at 8:23 PM
$ABEO microcap biotech low attention watching for speculative squeeze
0 · Reply
Buyorsell4321
Buyorsell4321 Feb. 3 at 5:09 PM
$ABEO any day now the news will send this flying in IMO 🚀
2 · Reply
Marcel20
Marcel20 Feb. 3 at 4:28 PM
$ABEO to the moon soon🚀
0 · Reply
TragicRain
TragicRain Feb. 3 at 4:13 PM
$ABEO - You ok....want to do some Happy Happy Change of mind....we accept all...
1 · Reply
TragicRain
TragicRain Feb. 3 at 4:12 PM
$ABEO - Anyone see the bearish investor....he got quiet....
0 · Reply
jaykza
jaykza Feb. 3 at 3:42 PM
$ABEO The Executives then the Board all received vested shares. They were able to cover the tax liability associated with that by selling a portion of the shares they received. The only signal I see is a positive one from Mark Alvino who normally sells his stock regularly. Often he delays sales for positive news events and sells into that. In this case, he paid a large portion of his tax liability, likely in cash, because he only sold 2k shares. The signal is he's likely delaying his regular sale for earnings or other news to maximize value.
0 · Reply
commoncentsinvestor
commoncentsinvestor Feb. 3 at 3:04 PM
$ABEO "Insiders at Abeona Therapeutics (ABEO) have recently sold shares primarily to cover tax obligations associated with the vesting of restricted stock awards."
0 · Reply
EMBERZZ
EMBERZZ Feb. 3 at 3:00 PM
$ABEO No one on this forum seems concerned regarding recent insider sells? Can you elaborate why? I want to share in the confidence here, but struggling đź«Ł
1 · Reply
Latest News on ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2025, 7:30 AM EST - 4 weeks ago

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

Dec 15, 2025, 7:30 AM EST - 7 weeks ago

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Dec 11, 2025, 7:30 AM EST - 7 weeks ago

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Dec 8, 2025, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead

Nov 12, 2025, 2:52 PM EST - 2 months ago

Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead

Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:11 PM EST - 2 months ago

Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Nov 12, 2025, 7:30 AM EST - 2 months ago

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Nov 7, 2025, 7:30 AM EST - 3 months ago

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

Oct 30, 2025, 10:45 AM EDT - 3 months ago

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Oct 20, 2025, 8:30 AM EDT - 3 months ago

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Oct 13, 2025, 7:30 AM EDT - 4 months ago

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Oct 8, 2025, 7:30 AM EDT - 4 months ago

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Aug 29, 2025, 7:30 AM EDT - 5 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 3:25 PM EDT - 6 months ago

Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript

Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn

Aug 15, 2025, 4:36 PM EDT - 6 months ago

Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Aug 14, 2025, 7:30 AM EDT - 6 months ago

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

Jul 29, 2025, 10:00 AM EDT - 6 months ago

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 15, 2025, 7:30 AM EDT - 7 months ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

Jul 14, 2025, 7:00 AM EDT - 7 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

TECH

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Jul 2, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Jul 1, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Jun 30, 2025, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Jun 24, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)

Jun 5, 2025, 5:48 AM EDT - 8 months ago

Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

May 30, 2025, 8:46 AM EDT - 8 months ago

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 16, 2025, 1:37 AM EDT - 9 months ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 15, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 8:07 AM EDT - 9 months ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

May 12, 2025, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Apr 30, 2025, 4:41 PM EDT - 9 months ago

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:06 AM EDT - 10 months ago

US FDA approves Abeona's skin disorder therapy

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Apr 29, 2025, 6:00 AM EDT - 10 months ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

Apr 27, 2025, 8:30 AM EDT - 10 months ago

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

DDD TKR KARO NNDM ORC PAA PAGP

Pz-Cel Has Massive Potential For RDEB Patients

Apr 21, 2025, 10:00 AM EDT - 10 months ago

Pz-Cel Has Massive Potential For RDEB Patients

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Apr 12, 2025, 11:39 AM EDT - 10 months ago

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 3:20 PM EDT - 11 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 20, 2025, 7:30 AM EDT - 11 months ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Mar 4, 2025, 9:00 AM EST - 1 year ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Jan 24, 2025, 12:40 PM EST - 1 year ago

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 12, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Announces Participation in November Investor Conferences

Nov 4, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Oct 3, 2024, 8:09 AM EDT - 1 year ago

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Aug 12, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

Jul 12, 2024, 4:59 PM EDT - 1 year ago

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

William_55555
William_55555 Feb. 3 at 9:15 PM
$ABEO what does Greg Gin at company IR do alp day? Clearly scroll on instagram. Guy has got such a cake job
1 · Reply
Pharma3000
Pharma3000 Feb. 3 at 8:49 PM
$ABEO Just waitđź‘Ś
0 · Reply
StricklandTrades
StricklandTrades Feb. 3 at 8:23 PM
$ABEO microcap biotech low attention watching for speculative squeeze
0 · Reply
Buyorsell4321
Buyorsell4321 Feb. 3 at 5:09 PM
$ABEO any day now the news will send this flying in IMO 🚀
2 · Reply
Marcel20
Marcel20 Feb. 3 at 4:28 PM
$ABEO to the moon soon🚀
0 · Reply
TragicRain
TragicRain Feb. 3 at 4:13 PM
$ABEO - You ok....want to do some Happy Happy Change of mind....we accept all...
1 · Reply
TragicRain
TragicRain Feb. 3 at 4:12 PM
$ABEO - Anyone see the bearish investor....he got quiet....
0 · Reply
jaykza
jaykza Feb. 3 at 3:42 PM
$ABEO The Executives then the Board all received vested shares. They were able to cover the tax liability associated with that by selling a portion of the shares they received. The only signal I see is a positive one from Mark Alvino who normally sells his stock regularly. Often he delays sales for positive news events and sells into that. In this case, he paid a large portion of his tax liability, likely in cash, because he only sold 2k shares. The signal is he's likely delaying his regular sale for earnings or other news to maximize value.
0 · Reply
commoncentsinvestor
commoncentsinvestor Feb. 3 at 3:04 PM
$ABEO "Insiders at Abeona Therapeutics (ABEO) have recently sold shares primarily to cover tax obligations associated with the vesting of restricted stock awards."
0 · Reply
EMBERZZ
EMBERZZ Feb. 3 at 3:00 PM
$ABEO No one on this forum seems concerned regarding recent insider sells? Can you elaborate why? I want to share in the confidence here, but struggling đź«Ł
1 · Reply
FitzCatalyst
FitzCatalyst Feb. 3 at 2:52 PM
$ABEO
0 · Reply
Filvul
Filvul Feb. 3 at 2:43 PM
$ABEO 3 Best Stocks to Buy Today, 2/3/2026, According to Top Analysts - TipRanks.com https://share.google/jFNLxtoeOKdAGv77V
0 · Reply
invest2021_now
invest2021_now Feb. 3 at 2:41 PM
$ABEO Bought more!
0 · Reply
TragicRain
TragicRain Feb. 3 at 2:35 PM
$ABEO - Getting that "Happy Happy Dance" warmed up.....
0 · Reply
edelhead
edelhead Feb. 3 at 1:09 PM
$ABEO More great data from Ultragenyx about UX111 in a press release this morning. I do fully expect FDA to approve this. Abeona had licensed UX111 to them, so this matters!
0 · Reply
TragicRain
TragicRain Feb. 3 at 12:34 PM
$ABEO - feeling like today is gonna be a Happy day....no real reason....just a good feeling....Hope it pans out....
1 · Reply
Filvul
Filvul Feb. 2 at 10:03 PM
$ABEO so many SEC fillings....
1 · Reply
stockinvestor102
stockinvestor102 Feb. 2 at 8:58 PM
$ABEO bought more.
0 · Reply
TragicRain
TragicRain Feb. 2 at 5:22 PM
$ABEO - Its cold outside...but the "Happy Happy Dance" keeps you warm.....
0 · Reply
Filvul
Filvul Feb. 1 at 6:49 PM
$ABEO What do you guys think, are we gonna get one more QTC by the end of the month, or no?? Radio silence ill next ER?!
1 · Reply
edelhead
edelhead Feb. 1 at 3:45 PM
$ABEO With UX111 resubmitted, it does make me wonder if at some point this year Ultragenyx acquires Abeona. It's one way to avoid making $30 million in milestone payments and 10% in royalties. Ultragenyx deals only with rare diseases and they currently have no dermatology-related treatments in their pipeline. AND Eric Crombez is on Abeona's board of directors and he happens to be the Chief Medical Officer of Ultragenyx. I'm not sure that Ultragenyx can afford Abeona, but it's something that would make sense if doable.
4 · Reply
FitzCatalyst
FitzCatalyst Jan. 30 at 6:34 PM
$ABEO hanging in there well… considering market/sector
0 · Reply